Major Breakthrough in Treating the "King of Cancers"! Daraxonrasib Reshapes the Pancreatic Cancer Landscape — Is the RAS R&D Track Ready?
Daraxonrasib (development code RMC-6236)is an orally active, non-covalent RAS(ON) inhibitor developed by Revolution Medicines, and an investigational oral anticancer drug.
In the field of targeted cancer therapy, it is regarded as a major breakthrough, especially for patients with pancreatic cancer and some non-small cell lung cancer (NSCLC) who have long lacked effective targeted drugs.
Chemical structure of Daraxonrasib (RMC-6236).
Source: Wikipedia
On May 31, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, principal investigator Dr. Brian Wolpin presented the key data for this drug, receiving a standing ovation from the researchers and physicians in attendance. Clinical trial data showed that Daraxonrasib nearly doubled patient survival and was hailed as a "game changer."
At the ASCO 2026 Plenary Session held in Chicago, researchers reported that in patients with metastatic pancreatic cancer, daraxonrasib nearly doubled overall survival compared with chemotherapy. After the presentation, attendees gave a standing ovation. Source: KBR (https://www.koreabiomed.com)
The FDA has granted Daraxonrasib Breakthrough Therapy designation and Orphan Drug designation for the treatment of patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) harboring G12 mutations.
▌Let the Data Speak: How Big Is This Breakthrough?
The Phase 3 RASolute 302 trial enrolled previously treated patients with metastatic pancreatic cancer; the core data for the RAS G12 mutation subgroup are as follows:
Survival time directly doubled, and the risk of death was reduced by 60%.
Safety was also superior to chemotherapy: the discontinuation rate due to side effects was only 1.2%, compared with as high as 11.2% in the chemotherapy group.
Earlier Phase 1/2 data showed that, for patients harboring any RAS mutation, the disease control rate (DCR) reached 95%, with a 6-month survival rate of 100%.
▌Mechanistic Breakthrough: How Does the "Molecular Glue" Lock Down RAS?
To understand why Daraxonrasib is so different, one must first understand why KRAS is so difficult to target.
The surface of the KRAS protein is smooth and lacks the binding pockets of traditional small-molecule drugs. For the past four decades, it has been almost a "forbidden zone" in the pharmaceutical industry.
Daraxonrasib's solution is to bypass the frontal attack and use a ternary complex (TCI) mechanism instead:
After entering the cell, it first binds to the intracellular chaperone protein Cyclophilin A (CypA) to form a binary complex; this complex then specifically captures RAS in the activated state (RAS(ON)), and the three interlock to form a stable ternary complex — like molecular glue, firmly locking the RAS protein that is sending out oncogenic signals.
Schematic diagram of the ternary complex inhibition mechanism of Daraxonrasib
The core advantage of this mechanism lies in its broad spectrum:
Wild-type KRAS / NRAS / HRAS, as well as activated RAS across the G12 / G13 / Q61 mutant subtypes, can all be covered.
This is something the earlier G12C-selective covalent inhibitors (Sotorasib, Adagrasib) could not achieve — the latter two can only hit the single G12C point.
▌CATO: In Step with the RAS Inhibitor R&D Wave
As the global RAS target pipeline advances at full speed, the corresponding impurity profile research needs have also emerged. CATO holds CNAS + ANAB dual-accredited ISO 17034 qualifications and is deeply rooted in the field of drug impurity reference standards, covering the full-cycle needs of API and formulation impurity profile research.
As Daraxonrasib's Phase 3 data were announced, CATO has simultaneously launched the series of impurity reference standards:
More RAS/KRAS inhibitor series impurity reference standards are under continuous development; inquiries for custom needs are welcome.